The All Wales Medicines Strategy Group started the assessment of ivacaftor (Kalydeco) as soon as the drug company formally engaged with the appraisal process. This process is recognised to be robust and normally takes about 21 weeks to allow all parties, including patient organisations such as the Cystic Fibrosis Trust, to submit their comments. The final appraisal decision for Kalydeco is scheduled to be reached at a public meeting on 8th May 2013.
More top news
Showers this evening could be heavy and thundery in places, but will gradually die out. A dry and warm day tomorrow, with some sunshine
This year's GCSE results have been described as 'stable' after years of focus on standards and performance.
A group of women from Rhyl have formed their own support group to fight back against body shaming.